When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Kathleen Mary,Noon

第一单位： a Costello Medical Consulting Ltd , London , UK.

作者： Kathleen Mary,Noon ^[1] ; Stephen Maxwell,Montgomery ^[2] ; Nicholas Edward,Adlard ^[3] ; Michel Anton,Kroes ^[4]

作者单位： a Costello Medical Consulting Ltd , London , UK. ^[1] b Costello Medical Consulting Ltd , Cambridge , UK. ^[2] c Novartis Pharma AG , Basel , Switzerland. ^[3] d Novartis Pharmaceuticals UK Ltd , Surrey , UK. ^[4]

关键词 C52 Cost-effectiveness I19 disease-modifying therapy economic modeling multiple sclerosis

主题词成年人(Adult);费用效益分析(Cost-Benefit Analysis);女(雌)性(Female);卫生资源(Health Resources);卫生服务(Health Services);人类(Humans);免疫抑制剂(Immunosuppressive Agents);男(雄)性(Male);Markov链(Markov Chains);模型, 经济学(Models, Economic);多发性硬化, 复发缓解性(Multiple Sclerosis, Relapsing-Remitting);技术评估, 生物医学(Technology Assessment, Biomedical)

DOI 10.1080/13696998.2018.1491007

PMID 29923439

发布时间 2019-01-14

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览6

Journal of medical economics

2018年21卷10期

983-992页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.

Journal of medical economics

相似文献

Journal of medical economics

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis.

Journal of medical economics

相似文献

Journal of medical economics

相关期刊

检索历史清除